hcc

Documents about hcc

• Netrin-1 & Hepatocellular Carcinoma HCC#993001ClinicalTrials.gov
• AI Multitask Model for HCC Treatment#912903ClinicalTrials.gov
• Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection#869415ClinicalTrials.gov
• Retrospective Clinical Validation of HepatoPredict#850431ClinicalTrials.gov
• Neoadjuvant Anti-PD1 in HCC#256898ClinicalTrials.gov
• Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC#303734ClinicalTrials.gov
• ALBI and PALBI Scores and HCC Prognosis#868854ClinicalTrials.gov
• Same-day Radioembolization for Large HCC#879772ClinicalTrials.gov
• Y90 Radiation Segmentectomy vs SBRT for HCC#966374ClinicalTrials.gov
• FMT in IT-refractory HCC - FAB-HCC Pilot Study#909968ClinicalTrials.gov
• Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma#892263ClinicalTrials.gov
• Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection#889656ClinicalTrials.gov
• SBRT in HCC With Oligoprogression on First-line Immunotherapy#414492ClinicalTrials.gov
• Predictors of Sorafenib Response in HCC#909578ClinicalTrials.gov
• A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer#842478ClinicalTrials.gov
• DNP-MRSI of HCC Metabolism to Predict Therapeutic Response#812606ClinicalTrials.gov
• Predictors of HCC in Post-HCV Cirrhotic Patients After SVR#916089ClinicalTrials.gov
• Novel Biomarker Assay for Biomarker Assay for HCC Detection#911914ClinicalTrials.gov
• Individualized Surgical Guidance in HCC-BDTT#992346ClinicalTrials.gov
• Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)#429763ClinicalTrials.gov
• Sequential TACE and SBRT Followed by ImmunoTherapy for Downstaging HCC for Hepatectomy#454042ClinicalTrials.gov
• Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC#842887ClinicalTrials.gov
• The Utility of Breath Biopsy as a Screening Tool for HCC#861064ClinicalTrials.gov
• Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)#892110ClinicalTrials.gov
• SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis#146433ClinicalTrials.gov
• Therapeutic Effects of Immuno-targeted Therapy Combined With or Without RT for HCC#195308ClinicalTrials.gov
• Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC#287539ClinicalTrials.gov
• Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC#432874ClinicalTrials.gov
• Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)#842976ClinicalTrials.gov
• CT Perfusion Parameters for Advanced HCC Treated by Systemic Immunotherapy#912484ClinicalTrials.gov
• A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment#981143ClinicalTrials.gov
• Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC#67884ClinicalTrials.gov
• Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma#807035ClinicalTrials.gov
• Defining the Ablative Dose for Y-90 TARE#834324ClinicalTrials.gov
• GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC#888109ClinicalTrials.gov
• Optimization for Regorafenib in HCC#911847ClinicalTrials.gov
• Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients#994395ClinicalTrials.gov
• Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN#845517ClinicalTrials.gov
• RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection#911209ClinicalTrials.gov
• Combine TACE and RFA Versus TACE Alone for HCC With PVTT#829396ClinicalTrials.gov
• WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy#154650ClinicalTrials.gov
• Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC#432871ClinicalTrials.gov
• PERSoN4: A multiparametric ultrasound model to improve CEUS LI-RADS for HCC#464460IRIS
• TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria#828016ClinicalTrials.gov
• Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk#889020ClinicalTrials.gov
• Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC#860170ClinicalTrials.gov
• TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension#841260ClinicalTrials.gov
• Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.#877383ClinicalTrials.gov
• A Prospective Observational Study on Efficacy of TARE for Early Stage HCC#889071ClinicalTrials.gov
• NWRD06 DNA Plasmid for HCC After Curative Resection.#901334ClinicalTrials.gov